Response to imatinib mesylate in chronic myeloid leukemia patients with variant BCR-ABL fusion transcripts

Annals of Hematology

Volumn 89, Issue 3, 2010, Pages 241-247

  Sharma, Pratibha ^a   Kumar, Lalit ^a   Mohanty, Sujata ^a   Kochupillai, Vinod ^a  

^a INSTITUTE ROTARY CANCER HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; HEMOGLOBIN; HYDROXYUREA; IMATINIB; MESSENGER RNA; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ADOLESCENT; ADULT; ARTICLE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOGENETICS; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN CELL; LEUKEMIA REMISSION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN SIZE; TREATMENT RESPONSE; CHROMOSOME ANALYSIS; CLINICAL TRIAL; GENETIC VARIABILITY; GENETICS; MIDDLE AGED; PHARMACOGENETICS; REMISSION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; CYTOGENETIC ANALYSIS; FEMALE; FUSION PROTEINS, BCR-ABL; GENETIC VARIATION; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PHARMACOGENETICS; PIPERAZINES; PYRIMIDINES; REMISSION INDUCTION; RNA, MESSENGER; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77949311884     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-009-0822-7     Document Type: Article

References (25)

1. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL (2001) Efficacy and safety of a specific inhibitor of the BCRABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031-1037
2. Savage DG, Antman KH (2002) Imatinib mesylate-a new oral targeted therapy. N Engl J Med 346(9):683-693
3. Deininger MW, Goldman JM, Melo JV (2000) The molecular biology of chronic myeloid leukemia. Blood 96(10):3343-3356
4. Melo JV (1996) The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood 88(7):2375-2384
5. Morris SW, Daniel L, Ahmed C et al (1990) Relationship of the bcr breakpoint to chronic phase duration, survival and blast lineage in chronic myelogenous leukemia patients presenting in early chronic phase. Blood 75:2035-2041
6. Baccarni M, Sagio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F et al (2006) Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European leukemia. Net Blood 108:1809-1820
7. Moorhead PS, Nowell PC, Mellman WJ, Battips DM, Hungerford DA (1960) Chromosome preparations of leukocyte cultured from human peripheral blood. Exp Cell Res 20:613-616
8. Seabright M (1971) A rapid banding technique for human chromosomes. Lancet 2(7731):971-972
9. Kaeda J, Chase A, Goldman JM (2002) Cytogenetic and molecular monitoring of residual disease in chronic myeloid leukaemia. Acta Haematol 107(2):64-75
10. van Dongen JJ, Macintyre EA, Gabert JA, Delabesse E, Rossi V, Saglio G et al (1999) Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease:report of the BIOMED-1 concerted action: investigation of minimal residual disease in acute leukemia. Leukemia 13(12):1901-1928
11. Gabert J, Beillard E, van der Velden VJH, Grimwade WBD, Barbany NPG, Cazzaniga G et al (2003) Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia-a Europe against cancer program. Leukemia 17(12):2318-2357
12. Lee M, Kantarjian H, Talpaz M et al (1992) Association of the responsiveness to interferon therapy with the bcr/abl splicing pattern in Philadelphia chromosome positive chronic myelogenous leukemia. Blood 80(suppl.I):210a
13. Shephered P, Suffolk R, Halsey J, Allan N (1995) Analysis of molecular breakpoint and m-RNA transcripts in a prospective randomized trial of interferon in chronic myeloid leukaemia: no correlation with clinical features, cytogenetic response, duration of chronic phase or survival. Br J Haematol 89(3):546-554
14. The Italian Cooperative Study Group on Chronic Myeloid Leukemia (1995) Chronic myeloid leukemia, BCR/ABL transcript, response to alpha-interferon and survival. Leukemia 9 (10):1648-1652
15. Prejzner W (2002) Relationship of the BCR gene breakpoint and the type of BCR/ABL transcript to clinical course, prognostic indexes and survival in patients with chronic myeloid leukemia. Med Sci Monit 8(5):BR193-BR197
16. Mondal BC, Bandyopadhyay A, Majumdar S, Mukhopadhyay A, Chandra S, Chaudhuri U et al (2006) Molecular profiling of chronic myeloid leukemia in eastern India. Am J Hematol 81(11):845-849
17. de Lemos JA, de Oliveira CM, Scerni AC, Bentes AQ, Beltrao AC, Bentes IR (2005) Differential molecular response of the transcripts B2a2 and B3a2 to Imatinib mesylate in chronic myeloid leukemia. Genetics and Molecular Research 4(4):803-811
18. Lomaia EG, Martinkevich IS, Ogorodnikova YS, Lyschov AA, Bogdanov KV, Zaritskey AY (2006) b2a2 Type bcr-abl transcript chronic myelogenous leukemia (CML) patients in chronic phase (CP) on Glivec achieve complete cytogenetic remission (CCyR) earlier than those with b3a2. Blood 108(suppl.): abstract 4780
19. Vega-Ruiz A, Kantarjian H, Shan J, Wierda W, Burger J, Verstovsek S et al (2007) Better molecular response to imatinib for patients (pts) with chronic myeloid leukemia (cml) in chronic phase (cp) carrying the b3a2 transcript compared to b2a2. Blood 110(suppl.): abstract 1939
20. Khorashad JS, Lavallade H, Apperley JF, Milojkovic D, Reid AG, Bua M et al (2008) Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression. J Clin Oncol 26(28):1-8
21. Polampalli S, Choughule A, Negi N, Shinde S, Baisane C, Amre P et al (2008) Analysis and comparison of clinic-hematological parameters and molecular and cytogenetic response of two Bcr/Abl fusion transcripts. Genet Mol Res 7(4):1138-1149
22. Perego RA, Costantini M, Cornacchini G, Gargantini L, Bianchi C, Pungolino E et al (2000) The possible influences of B2A2 and B3A2 BCR/ABL protein structure on thrombopoiesis in chronic myeloid leukemia. Eur J Cancer 36(11):1395-1401
23. Verschraegen CF, Kantarjian HM, Ginsberg CH, Lee MS, O'Brien S, Rios MB et al (1995) The breakpoint cluster region site in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer 76:992-997
24. Kumar L (2006) Chronic myelogenous leukemia (CML): an update. Nat Med J India 19:255-263
25. Vefring HK, Gruber FX, Wee L et al (2009) Chronic myelogenous leukemia with the e6a2 BCR-ABL and lacking Imatinib response: presentation of two cases. Acta Haematol 122(1):11-16